Render Target: STATIC
Render Timestamp: 2024-12-02T10:52:59.056Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-09-30 01:56:39.051
Product last modified at: 2024-10-18T13:00:11.822Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FGF19 (D1N3R) Rabbit mAb #83348

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 22
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FGF19 (D1N3R) Rabbit mAb recognizes endogenous levels of total human FGF19 protein. This antibody does not cross-react with the mouse ortholog FGF15.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala148 of human FGF19 protein.

    Background

    FGF19 is a member of the large and diverse Fibroblast Growth Factor (FGF) family of peptide growth factors. FGF19 functions as a high affinity ligand for the FGF4 receptor, to which it binds in a heparin-dependent manner (1). Under normal physiological conditions, FGF19 is produced in the ileum when absorbed bile acids bind to the farnesoid X receptor (FXR), activating transcription of the FGF19 gene. FGF19 in turn functions in a negative feedback fashion to regulate bile acid synthesis (2). Consequently, disruptions in FGF19 signaling have been linked with clinical defects in bile acid synthesis, which may manifest as primary bile acid diarrhea or cholestasis (3,4). Research studies in oncology have shown that FGF19 can function in an endocrine, paracrine or autocrine fashion to promote tumorigenesis. In human studies, this has been demonstrated for breast cancer (5), gastric cancer (6) prostate cancer (7, 8), and hepatocellular carcinoma (9). Similar tumorigenic effects have been described for the mouse ortholog (Fgf15), notably in genetic models of hepatocellular carcinoma (10, 11)
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.